"Our acquisition of Hu14.18, the group's second product for treatment of a rare disease, and the first development-stage asset in our portfolio, is a significant milestone," remarked Essential CEO Emma Johnson. Hu14.18 "has already produced positive data in Phase II clinical trials, demonstrating a significant improvement in survival, and we are now committed to developing this immunotherapy to be able to bring it to market."
A Phase II trial incorporating Hu14.18 into first-line therapy and within post-consolidation therapy for patients with high-risk neuroblastoma showed positive patient outcomes with 73.7% three-year event-free survival and 86% overall survival (OS). The trial is approaching the five-year OS readouts.
Under the deal, Renaissance CEO Simon Ball will continue to work with Essential on the development of Hu14.18, as will many of the Renaissance team. Essential will work with St Jude Children’s Hospital in accordance with their 2023 exclusive license agreement to drive the development and commercialisation of Hu14.18 across the territories licensed to Renaissance. Essential will be responsible for clinical development of Hu14.18 along with defining the optimal route for regulatory approval and commercial launch of the immunotherapy.